Follow Feed 커뮤니티에서 거래자 및 투자자와 연결하세요.
포괄적인 옵션 데이터를 탐색하고 옵션 흐름으로 고급 필터를 사용하세요.
터미널 모니터로 주식 및 자산 관심 목록을 구성하고 모니터링하세요.
NeuroVive Pharmaceutical AB Year End Report January - December 2019 PR Newswire STOCKHOLM, Feb. 19, 2020 STOCKHOLM, Feb. 19, 2020 /PRNewswire/...
NeuroVive Completes Recruitment in the Second Part of its Ongoing KL1333 Clinical Phase Ia/b Study PR Newswire LUND, Sweden, Dec. 20, 2019 LUND...
NeuroVive Announces Settlement in Dispute With CicloMulsion AG PR Newswire LUND, Sweden, Dec. 16, 2019 LUND, Sweden, Dec. 16, 2019 /PRNewswire/...
NeuroVive Pharmaceutical AB Interim Report January - September 2019 PR Newswire STOCKHOLM, Nov. 20, 2019 - Continued Progress in KL1333...
NeuroVive Pharmaceutical AB Interim Report January - September 2019 Continued Progress in KL1333 PR Newswire STOCKHOLM, Nov. 20, 2019 STOCKHOLM...
NeuroVive Pharmaceutical AB Interim Report January - June 2019 PR Newswire STOCKHOLM, Aug. 21, 2019 Focus on genetic mitochondrial diseases...
NeuroVive Pharmaceutical AB Interim Report January - June 2019 Focus on genetic mitochondrial diseases PR Newswire STOCKHOLM, Aug. 21, 2019...
Save the Date: NeuroVive to host Capital Markets Day in Stockholm on 9 October, 2019 PR Newswire LUND, Sweden, Aug. 20, 2019 LUND, Sweden, Aug...
NeuroVive's NeuroSTAT Project Receives FDA Fast Track Designation PR Newswire LUND, Sweden, July 27, 2019 LUND, Sweden, July 27, 2019...
NeuroVive Initiates Second Part of its Ongoing KL1333 Phase Ia/b Clinical Study PR Newswire LUND, Sweden, 4 July 2019 LUND, Sweden, 4 July 2019...
귀하가 조회한 주식이 이 박스에 나타나며 쉽게 최근 시세로 돌아갈 수 있습니다.
도움 및 지원받기: kr-support@advfn.com
ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관